The Ohio State University pancreatic disorders network (OSU-PDN)

俄亥俄州立大学胰腺疾病网络 (OSU-PDN)

• 批准号: 9987079
• 负责人: DARWIN LEWIS CONWELL
• 金额: $ 28.83万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-28 至 2020-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9987079
• 关键词: ANXA5 gene; Abdominal Pain; Address; Adult; Biological Markers; Blood; Brittle diabetes; Childhood; Clinical; Clinical Cancer Center; Clinical Research; Clinical Sciences; Collaborations; Consult; Development; Diabetes Mellitus; Diagnosis; Diagnostic; Digestive System Disorders; Disease; Disease Progression; Early Diagnosis; Fibrosis; Funding; Gastroenterologist; Gastroenterology; Goals; Individual; Inflammation; Institution; Knowledge; Left; Liquid substance; Main pancreatic duct; Malignant Neoplasms; Malignant neoplasm of pancreas; Malnutrition; Medical; Medical Research; Medical center; Methods; Modernization; National Institute of Diabetes and Digestive and Kidney Diseases; Non-Insulin-Dependent Diabetes Mellitus; Ohio; Operative Surgical Procedures; Organ; Pancreas; Pancreatic Diseases; Pancreatic Polypeptide; Participant; Patient Triage; Patients; Pediatric Research; Peptides; Performance; Primary Care Physician; Proteins; Proteome; Proteomics; Protocols documentation; Publishing; Research; Research Infrastructure; Research Proposals; Resources; Risk; Secondary to; Serum; Services; Standardization; Testing; Translational Research; United States; United States National Institutes of Health; Universities; Urine; Validation; accurate diagnosis; base; biomarker panel; candidate marker; chronic pancreatitis; cohort; diagnostic biomarker; early detection biomarkers; pancreatic juice; programs; repository; research study; response; sample collection; translational study

Project Summary and Abstract (Initial Submission) The diagnosis of chronic pancreatitis and T3cDM remain two of the greatest challenges and unmet needs in modern gastroenterology. The focus of this U01 application from The Ohio State University is to form a strategic alliance among academic institutions in the United States. Our major goals are to address the research objectives and aims of the Consortium, and to be considered as a clinical center. Specifically, we a) describe The Ohio State University Pancreatic Disorders Network (OSU-PDN), b) propose two research studies for consideration by the Consortium and c) outline our clinical and translational research infrastructure. Several key experimental observations from our group in CP and T3cDM warrant confirmation [OSU- PDN] and validation [CSCPDPC-CCs] : 1) Proteomic analysis of pancreas fluid (PF) and urine (U) in CP subjects revealed statistically significant fold-changes in several pancreatic fluid proteins - SERPINA5, ANXA5, CST3 (candidate pancreatic fluid markers) and urine proteins - CPN2, A1AG1, AMYP (candidate urine markers) when compared to healthy controls and 2) A significant difference in serum pancreatic polypeptide response to a mixed meal was observed that may distinguish T3cDM from the much more prevalent T2DM. These preliminary observations are the focus of our research proposals for consideration by the Consortium Steering Committee. Our Clinical Center will be centrally coordinated by the Ohio State University Center for Clinical and Translational Science (CCTS/CTSA) in collaboration with other CTSAs from our “network partners” in the OSU-PDN and the Consortium. The CCTS/CTSA provides consulting services and access to clinical and translational research infrastructure. This unique resource will assist our team in communicating with the CDMC, DSMB and NIDDK central repository. Both research proposals from our network address gaps in knowledge and understanding of chronic pancreatitis, diabetes and pancreas cancer as outlined by the NIDDK- National Commission on Digestive Diseases, and are strategically aligned with the objectives of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Clinical Centers (CSCPDPC-CCs) (U01).

项目概要和摘要（首次提交） 慢性胰腺炎和T3 cDM的诊断仍然是两个最大的挑战， 现代胃肠病学中未满足的需求。本次俄亥俄州U 01申请的重点 州立大学将在美国的学术机构之间形成战略联盟。 我们的主要目标是解决研究目标和联盟的目标， 作为临床中心。具体来说，我们a）描述俄亥俄州州立大学 胰腺疾病网络（OSU-PDN），B）提出两项研究供考虑 和c）概述我们的临床和转化研究基础设施。几 我们小组在CP和T3 cDM中的关键实验观察值得证实[OSU- PDN]和验证[CSCPDPC-CC]：1）胰腺液（PF）和尿液的蛋白质组学分析 (U)在CP受试者中，几种胰液显示了统计学显著的倍数变化 蛋白质-SERPINA 5、ANXA 5、CST 3（候选胰液标志物）和尿蛋白- CPN 2、A1 AG 1、AMYP（候选尿液标记物），与健康对照相比，以及2）A 观察到血清胰多肽对混合膳食的反应有显著差异 这可能将T3 cDM与更普遍的T2 DM区分开来。这些初步 观测结果是我们研究建议的重点，供联合会考虑 指导委员会。我们的临床中心将由俄亥俄州政府集中协调 大学临床和转化科学中心（CCTS/CTSA）与 来自OSU-PDN和联盟中我们的“网络合作伙伴”的其他CTSA。的 CCTS/CTSA提供咨询服务以及临床和转化研究 基础设施演进这种独特的资源将有助于我们的团队与CDMC沟通， DSMB和NIDDK中央存储库。我们网络的两项研究提案都解决了差距 慢性胰腺炎，糖尿病和胰腺癌的知识和理解， 由NIDDK-国家消化系统疾病委员会概述，并在战略上 与慢性胰腺炎研究联盟的目标一致， 糖尿病和胰腺癌临床中心（CSCPDPC-CC）（U 01）。